Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Rhea-AI Summary

Exelixis (NASDAQ: EXEL) is scheduled to participate in multiple investor conferences in March 2023. The company will present at the Cowen 43rd Annual Health Care Conference on March 7 at 1:30 PM ET in Boston, and at the Barclays Global Healthcare Conference on March 14 at 1:35 PM ET in Miami. Additionally, Exelixis will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 1:20 PM ET. Investors can access the live webcasts and replays on the company’s website. Exelixis is committed to advancing cancer care through innovative therapies.

– Presentations to be webcast on www.exelixis.com –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:

• Cowen 43^rd Annual Health Care Conference: Exelixis is scheduled to present at 1:30 pm ET / 10:30 am PT on Tuesday, March 7 in Boston.
• 2023 Barclays Global Healthcare Conference: Exelixis is scheduled to present at 1:35 pm ET / 10:25 am PT on Tuesday, March 14 in Miami.
• Oppenheimer 33^rd Annual Healthcare Conference: Exelixis is scheduled to present virtually at 1:20 pm ET / 10:20 am PT on Tuesday, March 14.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX^® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on Twitter, like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006371/en/

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When will Exelixis present at the Cowen 43rd Annual Health Care Conference?

Exelixis will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 1:30 PM ET in Boston.

What time is Exelixis' presentation at the Barclays Global Healthcare Conference?

Exelixis is scheduled to present at the Barclays Global Healthcare Conference on March 14, 2023, at 1:35 PM ET in Miami.

Will Exelixis participate in any virtual conferences?

Yes, Exelixis will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 1:20 PM ET.

How can I access the Exelixis conference webcasts?

Investors can access the webcasts of Exelixis conferences by visiting their website at least 15 minutes prior to the presentations.

What is Exelixis known for?

Exelixis is known for its innovative oncology treatments, particularly its flagship product CABOMETYX.